OR WAIT null SECS
The patent includes the use of fibroblast cells and adjuvants such as peptides and hydroxychloroquine, which fuels the assembly of natural interferon to overpower the virus.
FibroGenesis, a regenerative medicine company located in Houston, TX, announced on April 1, 2020 that it has filed a provisional patent for peptides and adjuvants for augmentation of fibroblast therapy for COVID-19 treatment.
According to a company press release, the patent includes the use of fibroblast cells and adjuvants such as peptides and hydroxychloroquine, which fuel the assembly of natural interferon to overpower the virus. The patent also features methods for preventing infection, propagation, and pathology as a result of COVID-19.
"As we continue our accelerated preclinical program, we are discovering the superiority of fibroblasts over mesenchymal stem cells and the data is leading us toward multiple treatment options for the patient," said Tom Ichim, PhD, chief scientific officer of FibroGenesis, in the press release. "By including adjuvants such as peptides and hydroxychloroquine in our treatment we've seen added potency."
"We are working to expand our discoveries in the lab and accelerate the clinical development into a cure for COVID-19 using our advanced fibroblast cell therapy," added Pete O'Heeron, CEO, FibroGenesis, in the press release. "The war we are fighting, with this invisible enemy, will likely require a cocktail-based approach for victory. At FibroGenesis we are following the lead of Thomas Edison when he discovered the filament for the lightbulb; we are testing as many therapeutic combinations as possible, in search of the most efficient and effective cure. Enhancing the natural production of interferon combined with our previous work can be seen as a possible advancement toward a cure."